Ublituximab: Difference between revisions
Content deleted Content added
m →top: HTTP → HTTPS for World Health Organization, replaced: = http://www.who.int/ → =https://www.who.int/ |
No edit summary |
||
Line 48: | Line 48: | ||
It is in [[phases of clinical research|Phase 3 clinical trials]] for [[multiple sclerosis]].<ref>https://clinicaltrials.gov/ct2/show/NCT03277261</ref> |
It is in [[phases of clinical research|Phase 3 clinical trials]] for [[multiple sclerosis]].<ref>https://clinicaltrials.gov/ct2/show/NCT03277261</ref> |
||
It is also in Phase |
It is also in "U2" Phase 3 clinical trials for [[chronic lymphocytic leukemia]] in combination with Umbralisib. |
||
==See also== |
==See also== |
Revision as of 12:22, 14 December 2020
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (mouse/human) |
Target | CD20 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
KEGG | |
(what is this?) (verify) |
Ublituximab is an immunomodulator. It binds to CD20.[1]
It is in Phase 3 clinical trials for multiple sclerosis.[2]
It is also in "U2" Phase 3 clinical trials for chronic lymphocytic leukemia in combination with Umbralisib.
See also
References
- ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
- ^ https://clinicaltrials.gov/ct2/show/NCT03277261